Ravulizumab
R3918-PNH-2021
Phase 3 small_molecule active
Quick answer
Ravulizumab for Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Paroxysmal Nocturnal Hemoglobinuria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active